Nuwellis, Inc. (NUWE )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol NUWE
- Company Nuwellis, Inc.
- Price $14.8
- Changes Percentage -6.09
- Change -0.96
- Day Low $14.31
- Day High $16.5
- Year High $178.5
- Year Low $6.33
- Market Cap $70,754,656
- Price Avg 50 EMA (D) $22.23
- Price Avg 200 EMA (D) $45.47
- Exchange NASDAQ
- Volume 170,184
- Average Volume 969,080
- Open $15.25
- Previous Close $15.76
- EPS 15.01
- PE 0.99
- Earnings Announcement 2025-08-11 12:30:00
- Shares Outstanding $4,780,720
Company brief: NUWELLIS, INC. (NUWE )
- Healthcare
- Medical - Devices
- Mr. Nestor Jaramillo Jr.
- https://www.nuwellis.com
- US
- N/A
- 02-16-2012
- US67113Y4052
Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
NUWE Corporation News
Nuwellis Announces Termination of REVERSE-HF Clinical Trial to Focus on Strategic Growth in Outpatient Heart Failure Care
globenewswire.com -- WHO WHAT WHEN WHY Nuwellis, Inc. Termination of theREVERSE-HF clinicaltrial July 17, 2025 To redirect resources towardoutpatient markets where scalableimpact is highest. MINNEAPOLIS, July 17, 2025 ...
Nuwellis Secures New U.S. Patent, Strengthening Its Position as a Leader in Fluid Management Innovation
globenewswire.com -- WHO WHAT WHERE WHEN WHY Nuwellis, Inc. Issuance of U.S. Patent No. 12,357,734 United States Patent and Trademark Office July 15, 2025 To protect innovations in blood filtering system design and method...